Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478592 | 0.81 | CDK1 (0.50) | — | |
| SCHEMBL7063134 | 0.80 | PDPK1 (0.37) | PDPK1GDA | |
| SCHEMBL1377645 | 0.78 | PI4KA (0.49) | — | |
| SCHEMBL6684462 | 0.74 | PI4KA (0.60) | — | |
| SCHEMBL2179785 | 0.74 | PI4KA (0.46) | PDPK1GDA | |
| SCHEMBL27648253 | 0.73 | PNP (0.61) | — | |
| SCHEMBL3396382 | 0.73 | PNP (0.52) | PDPK1GDA | |
| SCHEMBL1766004 | 0.69 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL16513157 | 0.69 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL1705024 | 0.69 | PDPK1 (0.44) | PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 796 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108350-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | SEASUNBIO MATERIALS (KP) | 2023-04-06 | — | — | US | claimed |
| CN-114901673-A | Method for preparing solution phase peptide nucleic acid oligomer | 海阳生物材料有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-11118215-B2 | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds | NUEVOLUTION A/S (DK) | 2021-09-14 | — | — | US | claimed |
| US-20210163541-A1 | Method for Preparing PNA Oligomer | SEASUNBIO MATERIALS (KR) | 2021-06-03 | — | — | US | claimed |
| US-11001835-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2021-05-11 | — | — | US | claimed |
| US-20200263238-A1 | DETECTION OF MYCOPLASMA IN CELL CULTURES AND CELL CULTURE DERIVED BIOLOGICALS | AKRON BIOTECHNOLOGY LLC (US) | 2020-08-20 | — | — | US | claimed |
| US-10730906-B2 | Multi-step synthesis of templated molecules | NUEVOLUTIONS A/S (DK) | 2020-08-04 | — | — | US | claimed |
| US-10731151-B2 | Method for synthesising templated molecules | NUEVOLUTION A/S (DK) | 2020-08-04 | — | — | US | claimed |
| US-10077440-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2018-09-18 | — | — | US | claimed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | claimed |
| EP-1282639-A2 | POLYAMIDE NUCLEIC ACID DERIVATIVES, AGENTS AND METHODS FOR PRODUCING THE SAME | Aventis Pharma Deutschland GmbH (DE) | 2003-02-12 | — | — | EP | claimed |
| US-20030022172-A1 | Polyamide nucleic acid derivatives and agents and processes for preparing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | claimed |
| US-20020187473-A1 | Peptide nucleic acid for use in the treatment skin, inflammatory and vitiligo disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-12 | — | — | US | claimed |
| US-6465650-B1 | INTERMEDIATE STEPS IN PREPARING PEPTIDE NUCLEIC ACIDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-15 | — | — | US | claimed |
| EP-0672677-B1 | Polyamide-oligonucleotide derivatives, their production and use | AVENTIS PHARMA GMBH (DE) | 2002-07-03 | — | — | EP | claimed |
| US-6388061-B1 | INCLUDES RUTHENIUM TRIS(BIPYRIDYL) LABEL BONDED TO THE NITROGEN BASE | DAKO A/S (DK) | 2002-05-14 | — | — | US | claimed |
| WO-2001079249-A2 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH A NEGATIVE CHARGE, AGENTS AND METHODS FOR PRODUCING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-10-25 | — | — | WO | claimed |
| EP-1113021-A2 | Polyamide-oligonucleotide derivatives, their production and use | Aventis Pharma Deutschland GmbH (DE) | 2001-07-04 | — | — | EP | claimed |
| EP-0672701-B1 | PNA-synthesis using a base labile aminoprotecting group | HOECHST AG (DE) | 1999-07-28 | — | — | EP | claimed |
| EP-0672700-B1 | PNA-synthesis using an aminoprotecting group which is labile against weak acids | HOECHST AG (DE) | 1999-06-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163541-A1 | Method for Preparing PNA Oligomer | NCL, NOD1, POLI | PDPK1 4061/4885GDA 394/4885 |
| US-20230108350-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | NCL, POLI, RNGTT | PDPK1 2571/4885GDA 380/4885 |
| US-10731151-B2 | Method for synthesising templated molecules | FGB, ILK, TBCB | PDPK1 4426/4885GDA 898/4885 |
| US-20030022172-A1 | Polyamide nucleic acid derivatives and agents and processes for preparing them | PHAX, POLRMT, PNKP | PDPK1 640/4885GDA 165/4885 |
| US-10730906-B2 | Multi-step synthesis of templated molecules | COASY, DAP3, EMG1 | PDPK1 3573/4885GDA 861/4885 |
| US-20020187473-A1 | Peptide nucleic acid for use in the treatment skin, inflammatory and vitiligo disorders | SSB, POLI, POLRMT | PDPK1 299/4885GDA 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.